Shanghai Hua Tai Biotechnology

Shanghai Huatai Biopharmaceutical is a Chinese biotechnology company focused on the development of innovative thrombolytic drugs for cardiovascular and cerebrovascular diseases. Founded in 2001 and located in Shanghai's Zhangjiang Hi-Tech Park, the company is best known for developing Recombinant Human Pro-urokinase (rhProurokinase), marketed under the brand name Puroxin. This product is a second-generation thrombolytic agent that offers high fibrin specificity and a lower risk of bleeding compared to earlier treatments. The company was acquired by Tasly Pharmaceutical Group, which has integrated Huatai into its biological medicine division to drive further clinical expansion. Currently, Huatai is advancing its lead candidate for additional indications, including acute ischemic stroke and pulmonary embolism.